0
TCR2 Therapeutics Inc. Banner Image

TCR2 Therapeutics Inc. has reached its limit for free report views

Work for TCR2 Therapeutics Inc.? Upgrade Your Profile and unlock all your annual reports.

TCR2 Therapeutics Inc.

  • Ticker TCRR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
TCR2 Therapeutics Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigensMore (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
TCR2 Therapeutics Inc.

Most Recent Annual Report

TCR2 Therapeutics Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. TCR2 Therapeutics Inc. has reached its limit for free report views.

Older/Archived Annual Reports